» Articles » PMID: 29016905

Relative Abuse of Crush-Resistant Prescription Opioid Tablets Via Alternative Oral Modes of Administration

Overview
Journal Pain Med
Date 2017 Oct 11
PMID 29016905
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Some crush-resistant tablet formulations (CRTs) reduce prescription opioid abuse by nonoral routes of administration (ROAs), especially insufflation and injection, while oral abuse increases. Oral abuse involving product manipulation vs swallowing whole for CRTs and comparators was examined.

Methods: Abuse by oral modes of administration (e.g., swallowing whole, chewing, dissolving in the mouth), was examined using the ASI-MV, a computerized, clinical interview for adults in substance abuse treatment from January 2009 to March 2015. CRTs (reformulated oxycodone extended-release [ER], reformulated oxymorphone ER, and tapentadol ER) were compared with non-CRT versions, morphine ER, and oxycodone immediate-release single entity. Analyses employed descriptive statistics and logistic regression.

Results: Among 364,329 unique assessments, 18,135 patients reported oral abuse of the CRTs and comparators examined. CRTs had a higher prevalence of oral abuse involving product manipulation than comparators (P < 0.0001) among all abusers of product. Oral abuse involving product manipulation for CRTs was greater among the subset of patients reporting oral abuse and significantly higher than comparators (P < 0.003). CRTs were significantly less likely than comparators to be swallowed whole (P < 0.0001) and significantly more likely to be chewed (P < 0.003). CRTs were more likely to be dissolved in the mouth than most comparators.

Conclusions: Results suggest the need for abuse-deterrent formulations designed to reduce abuse by oral administration with product manipulation, such as chewing. Advances in this area may reduce the overall abuse of prescription opioids and interrupt the progression from abuse by swallowing whole to oral administration involving product manipulation and other ROAs.

Citing Articles

Review of Opioid Abuse-Deterrent Formulations: Impact and Barriers to Access.

Webster L, Gudin J J Pain Res. 2024; 17:1989-2000.

PMID: 38854928 PMC: 11162618. DOI: 10.2147/JPR.S457982.


Characteristics of adults reporting illicitly manufactured fentanyl or heroin use or prescription opioid misuse in the United States, 2019.

Jiang X, Guy Jr G, Dunphy C, Pickens C, Jones C Drug Alcohol Depend. 2021; 229(Pt A):109160.

PMID: 34740067 PMC: 8671312. DOI: 10.1016/j.drugalcdep.2021.109160.


Interpol review of controlled substances 2016-2019.

Jones N, Comparin J Forensic Sci Int Synerg. 2021; 2:608-669.

PMID: 33385148 PMC: 7770462. DOI: 10.1016/j.fsisyn.2020.01.019.


Strengths and weaknesses of existing data sources to support research to address the opioids crisis.

Smart R, Kase C, Taylor E, Lumsden S, Smith S, Stein B Prev Med Rep. 2020; 17:101015.

PMID: 31993300 PMC: 6971390. DOI: 10.1016/j.pmedr.2019.101015.


Evaluation of Abuse and Route of Administration of Extended-Release Tapentadol Among Treatment-Seeking Individuals, as Captured by the Addiction Severity Index-Multimedia Version (ASI-MV).

Vosburg S, Beaumont J, Dailey-Govoni S, Butler S, Green J Pain Med. 2019; 21(9):1891-1901.

PMID: 31617931 PMC: 7553020. DOI: 10.1093/pm/pnz250.


References
1.
Butler S, Budman S, Licari A, Cassidy T, Lioy K, Dickinson J . National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse. Pharmacoepidemiol Drug Saf. 2008; 17(12):1142-54. DOI: 10.1002/pds.1659. View

2.
Butler S, Zacharoff K, Charity S, Lawler K, Jamison R . Electronic opioid risk assessment program for chronic pain patients: barriers and benefits of implementation. Pain Pract. 2013; 14(3):E98-E105. DOI: 10.1111/papr.12141. View

3.
Hendriks V, Kaplan C, van Limbeek J, Geerlings P . The Addiction Severity Index: reliability and validity in a Dutch addict population. J Subst Abuse Treat. 1989; 6(2):133-41. DOI: 10.1016/0740-5472(89)90041-x. View

4.
Chou R, Fanciullo G, Fine P, Adler J, Ballantyne J, Davies P . Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009; 10(2):113-30. PMC: 4043401. DOI: 10.1016/j.jpain.2008.10.008. View

5.
Butler S, Black R, Serrano J, Folensbee L, Chang A, Katz N . Estimating attractiveness for abuse of a not-yet-marketed "abuse-deterrent" prescription opioid formulation. Pain Med. 2009; 11(1):81-91. DOI: 10.1111/j.1526-4637.2009.00737.x. View